Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
The first patient has been enrolled in SciSparc Ltd.'s clinical trial evaluating the effectiveness and safety of their CBD-based drug for treating children with autism spectrum disorder, marking a significant advancement in ASD treatment. CEO Oz Adler expressed excitement about this milestone, highlighting the potential impact of the SCI-210 therapy in managing ASD symptoms. The company plans to enroll 60 participants aged 5 to 18 for a 20-week trial, comparing SCI-210 therapy with standard CBD treatment, in collaboration with the National Autism Research Center. Partnering with Tikun Olam Cannbit Pharmaceuticals Ltd., SciSparc aims to bring SCI-210 to market in Israel initially, with global distribution pending regulatory approvals. Additionally, the company achieved patent approvals in Canada for their opioid and n-acylethanolamine combination for pain management, as well as validation for their core technology patent in 15 European countries, demonstrating their commitment to advancing cannabinoid-based therapeutics.
